American Journal of Physiology-Renal Physiology · 2007 · 35 citations · 31 references
MedicinePharmacologyUrologyMolecular PharmacologyRenal PathophysiologyUrolithiasisCystine StonesHereditary Renal DiseasesRenal Cystic DiseasesRenal PharmacologyRenal TransportersTransporter PharmacologyCystine SolubilityCystine Stone FormationCystine Stone PreventionCystine Transport DefectsD-penicillamine TherapyKnockout Mouse ModelsSlc7a9 MutationsSolubilization
Cystinuria is a hereditary disorder caused by a defect in the apical membrane transport system for cystine and dibasic amino acids in renal proximal tubules and intestine, resulting in recurrent urolithiasis. Mutations in SLC3A1 and SLC7A9 genes, that codify for rBAT/b(0,+)AT transporter subunits, cause type A and B cystinuria, respectively. In humans, cystinuria treatment is based on the prevention of calculi formation and its dissolution or breakage. Persistent calculi are treated with thiols [i.e., d-penicillamine (DP) and mercaptopropionylglycine (MPG)] for cystine solubilization. We have developed a new protocol with DP to validate our Slc7a9 knockout mouse model for the study of the therapeutic effect of drugs in the treatment of cystine lithiasis. We performed a 5-wk treatment of individually caged lithiasic mutant mice with a previously tested DP dose. To appraise the evolution of lithiasis throughout the treatment a noninvasive indirect method of calculi quantification was developed: calculi mass was quantified by densitometry of X-ray images from cystinuric mice before and after treatment. Urine was collected in metabolic cage experiments to quantify amino acids in DP-treated and nontreated, nonlithiasic mutant mice. We found significant differences between DP-treated and nontreated knockout mice in calculi size and in urinary cystine excretion. Histopathological analysis showed that globally nontreated mutant mice had more severe and diffuse urinary system damage than DP-treated mice. Our results validate the use of this mouse model for testing the efficacy of potential new drugs against cystinuria.
31
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
Sabine Steffens, Niels R. Veillard, Claire Arnaud et al. · Nature · 2005 · 477 citations
Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT
Lídia Feliubadaló, Jesús Purroy, F. Rousaud et al. · Nature Genetics · 1999 · 335 citations
Epidemiology of paediatric renal stone disease in the UK
Richard J. Coward · Archives of Disease in Childhood · 2003 · 243 citations · Full text
Medicine, Nephrology, Pediatrics +15